Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir

P Kar, V Knecht - Journal of computer-aided molecular design, 2012 - Springer
Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …
被引用次数：59 相关文章

Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir

P Kar, V Knecht - Journal of Computer-Aided Molecular …, 2012 - ui.adsabs.harvard.edu
Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …

Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir

P Kar, V Knecht - Journal of Computer-Aided Molecular …, 2012 - search.proquest.com
Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …

Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir

P Kar, V Knecht - Journal of Computer-Aided Molecular Design, 2012 - infona.pl
Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …

[引用][C] Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir

P Kar, V Knecht - Journal of Computer-Aided Molecular Design, 2012 - cir.nii.ac.jp
Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

[引用][C] Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir

P Kar, V Knecht - Journal of Computer-Aided Molecular Design, 2012 - pure.mpg.de
Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir :: MPG.PuRe
日本語 Help Privacy Policy ポリシー/免責事項 全文を含む 詳細検索ブラウズ ホーム 一時保存 (0)ツール …

Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.

P Kar, V Knecht - Journal of Computer-aided Molecular Design, 2012 - europepmc.org
Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …

Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.

P Kar, V Knecht - Journal of Computer-Aided Molecular …, 2012 - search.ebscohost.com
Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …

Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir

P Kar, V Knecht - Journal of computer-aided molecular …, 2012 - pubmed.ncbi.nlm.nih.gov
Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …

Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.

P Kar, V Knecht - Journal of Computer-Aided Molecular …, 2012 - search.ebscohost.com
Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the
affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to …